Provost of the Medical Campus and Dean, Boston University School of Medicine, John Sanson Professor of Health Sciences
Catherine and Clifford Goldsmith Professor of Urology, Professor of Oncology, Chairman Emeritus Department of Urology, The Mt. Sinai Medical Center
Karin Grunebaum Professor in Cancer Research, Emeritus;
Boston University School of Medicine
Elsie T. Friedman Professor of Pathology, Harvard Medical School;Director, Center for Excellence in Vascular Biology,Brigham and Women's Hospital
Harvard Medical School Dean for Graduate Education and Special Advisor for Global Programs;
Professor of Biological Chemistry and Molecular Pharmacology;
Professor of Medicine;
Physician, Brigham and Womens Hospital and Dana-Farber Cancer Institute;
Virginia and D.K. Ludwig Professor of Cancer Research and Teaching, Harvard Medical School. Senior Advisor to the Director, National Cancer Institute.
Director, Biotechnology Analyst, Deutsche Bank
Professor, Departments of Medicine and Pathology, Boston University School of Medicine
Karin Grunebaum (née Wassermann) was born in Berlin, Germany on September 2, 1918 – the second daughter of a prominent banker. Her apparently very beautiful and loving mother died of an unspecified illness when Karin was only 6 years old – which would prove to be a strange precursor to Karin’s own life.
In June 1958, at age 39, Karin Grunebaum, the mother of 4 and a loving wife, suddenly passed away from cancer only three months after giving birth to her youngest child. Because her pregnancy had masked the symptoms of cancer, the disease had already metastasized throughout her entire body by the time the cancer was diagnosed a month after giving birth. There was no way to know what type of cancer she had. The primary site of the malignancy remained unknown.
After Karin passed away, her husband, Fritz Grunebaum, established the Karin Grunebaum Cancer Research Foundation as a lasting memory to his beloved wife so that other families could avoid such a tragedy by helping to identify and treat all tumors regardless of location.
Because Karin Grunebaum died at age 39 from an unknown primary site malignancy, the overriding objective of the Karin Grunebaum Cancer Research Foundation is the eradication of all types of cancer. The Foundation's original Declaration of Trust, written in 1958, mandates that the Foundation's funds be exclusively used for "...aiding research in and study of the cause, treatment and cure of cancer."
The Foundation's Trustees firmly believe that the eradication of cancer will only occur through successful research accomplishments which are followed by successful practical/commercial application. Thus, the Foundation has chosen to invest its funds directly in dedicated cancer researchers in hope of helping them achieve significant accomplishments to eliminate all types of carcinomas and thereby eradicate each and every type of cancer.
The Foundation is very proud of the success achieved by our Fellows who have been working and teaching at some of the most prestigious and front-line cancer research facilities in the world, including: Adaptive Biotechnologies, AMGEN Corp, City of Hope, Dana-Farber Cancer Institute, Duke Health, Immune Design, Johns Hopkins, Massachusetts General Hospital, M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Merck & Co., Mersana Therapeutics, Mount Sinai School of Medicine, NYU Langone Medical Center, Siteman Cancer Center, SLJ Consulting, Stanford University Cancer Center, UC Irvine Health, UCLA Medical Center, University of California (San Francisco), University of Maryland School of Medicine, University of Pennsylvania School of Medicine, University ot Texas Health Science Center, University of Vermont Medical School, Vanderbilt University Medical Center, Weill Cornell Medical Center, Yale Cancer Center and Zyngenia Corporation, in addition to our sponsored institutions of Harvard Medical School and Boston University School of Medicine.
The support we are able to give to the dedicated cancer researchers is solely dependent on donations from you -- we have no other funding. Find out how you can make a tax-deductible contribution online or via mail on our Support and Contributions for the Grunebaum Foundation section
Whether you want to eliminate taxes or benefit from an increased income stream, there is a gift to fit every objective. Please review our Benefits of Giving to charitable organizations to learn how you can give as well as receive.
The following is a list of planned meetings.
If you are interested in the institutions our Fellows attend you can review the Universities our KGCRF Fellows attend here.
Fellowships are available to junior faculty members at Harvard Medical School and the Boston University School of Medicine. If you are interested in applying to become a Karin Grunebaum Fellow, please use the following links to the three institutions.Boston University
Notice of award for "Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)"
NIH Director's New Innovator Award
The Karin Grunebaum Chair in Cancer Research was established in 2002 at the Boston University School of Medicine. In July 2004, Boston University's Board of Trustees approved Professor Douglas Faller, Ph.D., M.D. as the first Karin Grunebaum Professor of Cancer Research. In addition, Dr. Faller serves on the Foundation's Board of Trustees.
This professorship represents the first in the field of Cancer Research at the Boston University School of Medicine.